ストックスクリーナーアプリを入手
21.08
1.84%
0.38
アフターアワーズ：
21.08
前日終値:
$20.70
開ける：
$20.51
24時間の取引高:
281.46K
Relative Volume:
2.06
時価総額：
$956.46M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+14.25%
1か月 パフォーマンス:
+49.61%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$20.25
$21.55
1週間の範囲:
$18.00
$21.55
52週間の値動き範囲:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
MPLT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
21.08 | 939.22M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-21 | 開始されました | Jefferies | Buy |
| 2025-11-21 | 開始されました | Leerink Partners | Outperform |
| 2025-11-21 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-21 | 開始されました | Stifel | Buy |
Maplight Therapeutics Inc (MPLT) 最新ニュース
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
MapLight Therapeutics completes IPO and raises $296.5M - MSN
Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Adversity is less terrifying than hope: MapLight Therapeutics Inc (MPLT) - setenews.com
MapLight Therapeutics Advances CNS Drug Pipeline - TipRanks
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat
Maplight Therapeutics reports third quarter financial results - marketscreener.com
MapLight Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
MapLight Therapeutics Completes IPO and Raises $296.5M - TipRanks
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - The Manila Times
MapLight Therapeutics, Inc. SEC 10-Q Report - TradingView
MPLT: Clinical pipeline advances and robust IPO funding position operations through 2027 - TradingView — Track All Markets
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts - TipRanks
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug - Investing.com Canada
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
SETIA VISHWAS Insider Trades - Nasdaq
MapLight Therapeutics (MPLT) Stock Analysis Report | Financials & Insights - Benzinga
MPLT Interactive Stock Chart | MapLight Therapeutics, Inc. Stock - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
MapLight Therapeutics Closes Successful IPO and Private Placement - MSN
FOFF ERIN PENNOCK Insider Trades - Nasdaq
KROEGER CHRISTOPHER A Insider Trades - Nasdaq
MapLight Therapeutics stock rating reiterated at Overweight by Morgan Stanley - Investing.com Canada
MapLight Therapeutics initiated with a Buy at Stifel - MSN
Jefferies & Co Initiates Coverage on MapLight Therapeutics With Buy Rating, $32 Price Target - marketscreener.com
Morgan Stanley Initiates MapLight Therapeutics at Overweight With $34 Price Target - marketscreener.com
MPLT Analyst Forecasts - Quiver Quantitative
This IBM Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
MapLight Therapeutics stock initiated with Outperform rating by Leerink Partners - Investing.com Canada
Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential - TipRanks
Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials - TipRanks
MapLight Therapeutics stock initiated with Buy rating at Jefferies By Investing.com - Investing.com Canada
MapLight Therapeutics stock initiated with Buy rating by Stifel - Investing.com Canada
Morgan Stanley initiates MapLight Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
MapLight Therapeutics, Inc. (MPLT) Balance Sheet - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Latest Press Releases & Corporate News - Yahoo! Finance Canada
MapLight Therapeutics, Inc. share price - Capital.com
Timothy John Garnett Net Worth (2025) - GuruFocus
Erin Pennock Foff Net Worth (2025) - GuruFocus
Anatol Kreitzer Net Worth (2025) - GuruFocus
Vishwas Setia Net Worth (2025) - GuruFocus
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More - AOL.com
MapLight Therapeutics, Inc. (MPLT) stock major holders - Yahoo Finance UK
Long term debt to total assets ratio of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Biopharma financings jump 86% in October, raising $13.2B - BioWorld MedTech
Maplight Therapeutics (MPLT) 10K Form and SEC Filings 2025 - MarketBeat
Maplight Therapeutics Inc (MPLT) 財務データ
Maplight Therapeutics Inc (MPLT) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.36%
1.05%
大文字化:
|
ボリューム (24 時間):